No profile data available.
Nutriband Inc. (NTRB) is a healthcare company in the healthcare equipment manufacturing contractors industry, based in Orlando, United States.
It reported revenue of $2.14 million for fiscal year 2025, up 2.6% from fiscal year 2024, and net income of -$10.48 million. In Q3 2026 (the quarter ended October 31, 2025) revenue was $346,058, down 46.4% from a year before. Its market capitalization was $80.84 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended January 31, 2025; market data as of October 9, 2026.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate.
Nutriband reported $2.14 million in revenue for fiscal year 2025, up 2.6% from $2.09 million in fiscal year 2024. In Q3 2026 revenue was $346,058.
$80.84 million as of October 9, 2026.
Listed companies of a similar size in the same industry (healthcare equipment manufacturing contractors) include Integer Holdings Corporation (ITGR), Varex Imaging Corporation (VREX), Pro-Dex, Inc. (PDEX), Precision Optics Corporation, Inc. (POCI).